Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Market Closed - Nasdaq Other stock markets 21:30:00 12/06/2025 BST			5-day change	1st Jan Change
8.470 ^USD	-0.24%		-5.89%	-62.81%

05-22	Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	CI
05-22	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	RE

Quoin Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Mar 14, 2024

Published on 14/03/2024 at 12:30

Presentation Operator Message
Operator (Operator)

Good day, and welcome to the Quoin Pharmaceuticals Fourth Quarter Financial Results and Business Update Conference Call. [Operator Instructions].

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	05-22	CI
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	RE
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	05-22	MT
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing	05-14	MT
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Quoin Pharmaceuticals Regains Compliance With Nasdaq	04-30	RE
Quoin Pharmaceuticals Changes ADS Ratio to Meet Nasdaq Rule	04-04	MT
Quoin Pharmaceuticals - Subject's Skin Almost Completely Healed After 6 Weeks Of Qrx003	04-02	RE
Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	04-02	CI
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	03-25	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-13	CI
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	03-04	CI
Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study	02-27	CI
Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	01-23	CI
Quoin Pharmaceuticals Ltd. Announces Positive Clinical Data from its Ongoing Pediatric Netherton Syndrome Study	01-16	CI
Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	01-06	CI
Quoin Pharmaceuticals Insider Bought Shares Worth $250,000, According to a Recent SEC Filing	12-27	MT
Quoin Pharmaceuticals Insider Bought Shares Worth $250,000, According to a Recent SEC Filing	12-27	MT
Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall	12-20	MT
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study	12-19	CI
Quoin Pharmaceuticals, Ltd. Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies	12-18	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-08	CI
Quoin Pharmaceuticals Seeks M&A Opportunities	11-06	CI
Quoin Pharmaceuticals Ltd. Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient	11-05	CI